Fosun-backed Shanghai Henlius Biotech has priced shares at the bottom of its range to raise $410m in its initial public offering ahead of public trading next week.

Shanghai Henlius Biotech, a China-based biotechnology developer backed by conglomerate Fosun, will raise $410m in its initial public offering, Reuters reported yesterday, citing people familiar with the matter. The company issued approximately 64.7 million shares priced at HK$49.60 ($6.34) and will begin trading on the Hong Stock Exchange on September 25. The share price represents…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.